Health Economics

This section of the ESCEO web site, devoted to health economics, will provide, on a regular basis, expert opinion, consensus statements and reprints of papers that either are produced by members of our Scientific Committee or that members of our Scientific Committee found of particular interest to the ESCEO members. The scope includes cost-effectiveness of interventions and the burden of disease from an economic perspective. Our objective is to provide you with clear and up-to-date, scientifically reliable information dealing with topics that are directly linked with the goals and missions of ESCEO.

Publications

DOWNLOAD	TITLE	AUTHORS
	Health Technology Assessment in Osteoporosis	M. Hiligsmann, J.A. Kanis, J. Compston, C. Cooper, B. Flamion, P; Bergmann, J.-J. Body, S. Boonen, O. Bruyère, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster
	Incidence and socioeconomic burden of hip fractures in Italy: extension study 2003-2005	P. Piscitelli, M.L. Brandi, U. Tarantino, A. Baggiani, A. Distante, M. Muratore, V. Grattagliano, A. Migliore, M. Granata, G. Guglielmi, R. Gimigliano, G. Iolascon
	Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis	B. Jönsson, O. Ström, J. A. Eisman, A. Papaioannou, E. S. Siris, A. Tosteson, J. A. Kanis.
	Validation of the IOF quality of life questionnaire for patients with wrist fracture	P. Lips, K. Jameson, M. L. Bianchi, S. Goemaere, S. Boonen, J. Reeve, J. Stepan, O. Johnell, N. M. van Schoor, E. Dennison, J. A. Kanis, C. Cooper, Working Group for Quality of Life of the International Osteoporosis Foundation.
	FRAX® and its applications in health economics - Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example	O. Ström, F. Borgström, M. Kleman, E. McCloskey, A. Odén, H. Johansson, J.A. Kanis.
	Osteoporosis: burden, health care provision and opportunities in the EU	O. Ström, F. Borgström, J. A. Kanis, J. Compston, C. Cooper, E. V. McCloskey, B. Jönsson.
	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women	J. A. Kanis, E. V. McCloskey, B. Jonsson, A. Cooper, O. Ström, F. Borgström
	The cost-effectiveness of alendronate in the management of osteoporosis	J. A. Kanis, J. Adams, F. Borgström, C. Cooper, Bengt Jönsson, D. Preedy, P. Selby, J. Compston.
	Reply to Letter to the Editor: Modelling cost-effectiveness in osteoporosis	J. A. Kanis, J. Adams, F. Borgström, C. Cooper, Bengt Jönsson, D. Preedy, P. Selby, J. Compston.
	An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting	F. Borgström, B. Jönsson, O. Ström, J. A. Kanis
	The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective	F. Borgström . Å. Carlsson . H. Sintonen . S. Boonen . P. Haentjens . R. Burge . O. Johnell . B. Jönsson . J. A. Kanis
	At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis	F. Borgström; O. Johnell, J. A. Kanis, B. Jönsson, C. Rehnberg
	Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial	N. Zethraeus, F. Borgström, B. Jönsson, J. A. Kanis
	Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK - Results based on the Women's Health Initiative randomised controlled trial	I. Lekander, F. Borgström, O. Ström, N. Zethraeus, J. A. Kanis
	Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK	I. Lekander, F. Borgström, O. Ström, N. Zethraeus, J. A. Kanis
	Glucocorticoid-induced osteoporosis: a systematic review and cost - utility analysis	J. A. Kanis, JE. Brazier, MD. Stevenson, E.V. McCloskey, S. Davis, M. Lloyd-Jones
	Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women	MD. Stevenson, JE Brazier, NW Calvert, M. Lloyd-Jones, JE Oakley, J. A. Kanis
	Incorporating adherence into health economic modelling of osteoporosis	O. Ström, F. Borgström, J. A. Kanis, B. Jönsson
	Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model	N. Zethraeus, F. Borgström, O. Ström, J. A. Kanis, B. Jönsson
	The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks	T.-P. van Staa, J. A. Kanis, P. Geusens, A. Boonen, H. G. M. Leufkens, C. Cooper
	Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature	M. Hiligsmann, O. Ethgen, F. Richy, J.-Y. Reginster
	Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications	M. Hiligsmann, V. Rabenda, H.-J. Gathon, O. Ethgen, J.-Y. Reginster
	Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis	M. Hiligsmann, O. Ethgen, O. Bruyere, F. Richy, H.-J. Gathon, J.-Y. Reginster
	An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis	M. Hiligsmann, O. Ethgen, O. Bruyere, J.-Y. Reginster
	Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years	M. Hiligsmann, O. Bruyere, J.-Y. Reginster
	Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women	M. Hiligsmann, O. Bruyere, J.-Y. Reginster
	The need for economic evaluation in osteoarthritis	O. Bruyere, J.-Y. Reginster
	Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis	O. Bruyere, S. Scholtissen, A. Neuprez, M. Hiligsmann, A. Toukouki, J.-Y. Reginster
	The risk and burden of vertebral fractures in Sweden	J.A. Kanis, O. Johnell, A. Oden, F. Borgstrom, N. Zethraeus, C. De Laet, B. Jonsson
	The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients	M. Hiligsmann, V. Rabenda, O. Bruyere, J.-Y. Reginster
	Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence	M. Hiligsmann, H.-J. Gathon, O. Bruyere, O. Ethgen, V. Rabenda, J.-Y. Reginster
	The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®	F. Borgström, O. Ström, J. Coelho, H. Johansson, A. Oden, E. V. McCloskey, J. A. Kanis
	The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis	F. Borgström, O. Ström, J. Coelho, H. Johansson, A. Oden, E. V. McCloskey, J. A. Kanis